Neuroimmunology: BÜHLMANN neural antibody ELISAs in the Literature – over 40 References

BÜHLMANN GanglioCombi™ ELISAs

  
  “BÜHLMANN GanglioCombi™ at the utmost importance of daily questions such as the differentiation between Multifocal Motor Neuropathies (MMN, treatable) and MMN- mimicking disorders such as Amyotrophic Lateral Sclerosis (ALS, not treatable). This is the biggest ALS cohort investigated to date and demonstrates that frequency of anti-Ganglioside antibodies is not different from apparently healthy normal blood donors.”

- Cao-Lormeau V. M. et al., 2016: Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 387(10027); 1531-1539 (incl supplement).

  “BÜHLMANN GanglioCombi™ at the forefront of newly emerging post-infectious forms of Guillain-Barré syndromes such as those associated with Zika viruses.


  “BÜHLMANN GanglioCombi ELISA compared to competitor Assays has best performance and qualifies for Assay of choice for daily clinical routine application.”

Further literature citing BÜHLMANN GanglioCombi™ ELISA/anti-GM1 autoantibody ELISA


- Lei T et al., 2012: Anti-ganglioside antibodies were not detected in human subjects infected with or vaccinated against 2009 pandemic influenza A (H1N1) virus. Vaccine 30: 2605-2610


- Wurster U et al., 2009: Ganglioside Antibodies in Amyotrophic Lateral Sclerosis. Poster presented at DAS, Dresden (GE).
BÜHLMANN anti-MAG Autoantibodies ELISA


  “BÜHLMANN anti-MAG ELISA is described as a reliable quantitative tool to differentiate anti-MAG neuropathy into typical anti-MAG neuropathy and high titres of anti-MAG antibodies and CIDP-like neuropathy, negative immune fluorescence (IF) results and low BTU titres.”


  “Increase of sensitivity and determination by co-measurement of anti-MAG with -ganglioside antibodies, in patients with demyelinating neuropathies and IgM monoclonal antibodies (IgM-PNP).


  “The article evaluates service provision and quality assurance schemes for clinically useful autoantibody test in neurology. ELISA is a widely used technique for the determination of anti-glycolipid antibodies and anti-MAG autoantibody ELISA “has good standardisation.”

- Kuijf M. et al., 2009: Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. Neurology 73(9) 688-695

  “Excellent differentiation between healthy subjects and patients with a demyelinating neuropathy with immunoglobulin M (IgM) monoclonal gammopathy (IgM-PNP) with an area under the curve of 0.84”


  “Monitoring Rituximab treatment is an important tool for patient management. During successful treatment, the measurement of anti-MAG autoantibodies by the BÜHLMANN assay shows significant decrease allowing follow-up of patients in therapy.”

Further literature citing anti-MAG autoantibody ELISA by BÜHLMANN


- Stork A. C. J. et al., 2016: Classiscal and lectin complement pathway activity in polyneuropathy associated with IgM monoclonal gammopathy. J Neuroimmunol 290: 76-79


• **Stork A. C. J. et al., 2014**: Clinical phenotype of patients with neuropathy associated with monoclonal gammopathy: a comparative study and a review of the literature. J Neurol 261(7): 1389-1404

• **Sala E. et al., 2014**: Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy. J Neurol Sci 345(1-2):224-227


• **Hospital M. A. et al., 2013**: Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients. Haematologica 98(12): e155-157

• **Piscosquito G. et al., 2013**: Coexistence of Charcot-Marie-Tooth disease type 1A and anti-MAG neuropathy. J Peripher Nerv Syst 18(2): 185-188

• **Stork A. C. J. et al., 2013**: Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment. J Peripher Nerv Syst 18(2): 189-192

• **Pihan M. et al., 2012**: [Neuropathies associated with monoclonal IgM anti-MAG antibodies]. Rev Med Interne; 33(12): 686-692

• **Maurer M. A. et al., 2012**: Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. J Clin Invest 122(4):1393-1402

• **Mostafa G. A. et al., 2012**: Reduced serum concentrations of 25-hydroxy vitamin D in children with autism: relation to autoimmunity. J Neuroinflammation 17(9): 201


• **Matà S. et al., 2011**: Anti-myelin associated glycoprotein antibodies recognize HNK-1 epitope on CNS. J Neuroimmunol 236(1-2): 99-105

• **Larue S. et al., 2011**: Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur J Neurol 18(6): 899-905

• **Matà S. et al., 2011**: IgM monoclonal gammopathy-associated neuropathies with different IgM specificity. Eur J Neurol 18(8): 1067-1073

• **Jurici S. et al., 2011**: An Autopsy Case of Amyotrophic Lateral Sclerosis with Waldenström Macroglobulinemia and Anti-MAG Gammopathy. Case Rep Neurol 3(3): 294-400


• **Théaudin M. et al., 2011**: Short and long-term effect of IVlg in demyelinating neuropathy associated with MGUS, experience of a monocentric study, Rev Neurol (Paris) 167(12): 897-904


- **Caudie C. et al., 2006**: [Diagnostic value of autoantibodies to MAG by ELISA Bühlmann in 117 immune-mediated peripheral neuropathies associated with monoclonal IgM to SGPG/SGLPG]. *Ann Biol Clin* **64**(4): 353-359

- **Kvarnström M. et al., 2002**: Myelin protein P0-specific IgM producing monoclonal B cell lines were established from polyneuropathy patients with monoclonal gammopathy of undetermined significance (MGUS). *Clin Exp Immunol* **127**(2): 255-262

**BÜHLMANN anti-SGPG Autoantibody ELISA**

- **Caudie C et al., 2007**: [Diagnostic value of the anti-IgM SGPG Elisa (BÜHLMANN Laboratories AG) in 147 sera with a monoclonal IgM anti-MAG/SGPG antibody-associated neuropathy]. *Ann Biol Clin (Paris)* **65**(4): 369-375

  "The anti-SGPG autoantibody ELISA by BÜHLMANN turned out to be a very reliable commercially available test with no technical difficulties and both, excellent sensitivity (0.98), and specificity (0.98) for detecting MAG/SGPG antibody-mediated demyelinating neuropathies. Anti-SGPG antibody titers have practical implications for both, management and follow-up of neuropathies treated with rituximab."


- **Kuijf M et al., 2009**: Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. *Neurology* **73**(9): 688-695

Please send your request for a copy to support@buhlmannlabs.ch